Dignitana (DIGN) Q3 2024 earnings summary

Executive summary

• Net sales increased 3% year-over-year to 22.8 MSEK in Q3 2024, with positive EBITDA and reduced net loss compared to Q3 2023.

• Strategic initiatives included cost optimization, organizational fine-tuning, and a new field service partnership in the US.

• Significant progress in reimbursement, including new AMA CPT codes and a 40% Medicare rate increase for scalp cooling.

• Expanded presence in Europe and Japan, with new device placements and partnerships.

Financial highlights

• Net sales: 22.8 MSEK (22.2), up 3% year-over-year; US market grew 5% in local currency.

• Operating result: -0.7 MSEK (-3.2); Net result after financial items: -1.5 MSEK (-3.7).

• EBITDA: 2.1 MSEK (0.7); EPS: -0.02 SEK (-0.05).

• Cash balance: 4.4 MSEK (7.0); cash flow from operating activities improved to 3.4 MSEK (-0.2).

• Average Daily Treatment Revenue: 231 TSEK (237); capex for Q3: 1.0 MSEK (1.4).

Outlook and guidance

• Management expects continued growth and profitability through strategic initiatives and business model optimization.

• Anticipates increased patient access and utilization as new reimbursement codes take effect in 2026.

• Ongoing efforts to secure additional funding to support operations and growth.